Cited by 1,357RNA Interference and Gene DeliveryVirus-based gene therapy researchRNA Research and Splicing

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

RNAi-mediated gene silencing in non-human primates

Zimmermann, Tracy S., Lee, Amy C. H., Akinc, Akin, Bramlage, Birgit, Bumcrot, David, Fedoruk, Matthew N., Harborth, Jens, Heyes, James A., Jeffs, Lloyd B., John, Matthias, Judge, Adam D., Lam, Kieu, McClintock, Kevin, Nechev, Lubomir V., Palmer, Lorne R., Racie, Timothy, Röhl, Ingo, Seiffert, Stephan, Shanmugam, Sumi, Sood, Vandana, Soutschek, Jürgen, Toudjarska, Ivanka, Wheat, Amanda J., Yaworski, Ed, Zedalis, William, Koteliansky, Victor, Manoharan, Muthiah, Vornlocher, Hans-Peter, MacLachlan, Ian·2006·Nature

DOI 10.1038/nature04688

Open this paper in CoChat — free account

Abstract

The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there are numerous examples of in vivo silencing of target genes after local delivery of small interfering RNAs (siRNAs), there remain only a few reports of RNAi-mediated silencing in response to systemic delivery of siRNA, and there are no reports of systemic efficacy in non-rodent species. Here we show that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B (ApoB) in non-human primates. APOB-specific siRNAs were encapsulated in stable nucleic acid lipid particles (SNALP) and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1). A single siRNA injection resulted in dose-dependent silencing of APOB messenger RNA expression in the liver 48 h after administration, with maximal silencing of >90%. This silencing effect occurred as a result of APOB mRNA cleavage at precisely the site predicted for the RNAi mechanism. Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels were observed as early as 24 h after treatment and lasted for 11 days at the highest siRNA dose, thus demonstrating an immediate, potent and lasting biological effect of siRNA treatment. Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.

Integrity signals

Registry

Crossref · 10.1038/nature04688

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
The RNAi revolution
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 739
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2004) · Nature Medicine · doi:10.1038/nm1164 · Cited by 731

Show all 20 references

Sorted by citations

Items 701–800 of 1,001

Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer
Rad, S. M. A. H., Langroudi, L., Kouhkan, F., Yazdani, L., Koupaee, A. N., Asgharpour, S., Shojaei, Z., Bamdad, T., & Arefian, E. (2015) · Tumor Biology · doi:10.1007/s13277-015-3344-z · Cited by 34
Identification of small interfering RNAs which inhibit the replication of several Enterovirus 71 strains in China
Wu, Z., Yang, F., Zhao, R., Zhao, L., Guo, D., & Jin, Q. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2009.04.002 · Cited by 33
RNAi as a new therapeutic strategy against HCV
Khaliq, S., Khaliq, S. A., Zahur, M., Ijaz, B., Jahan, S., Ansar, M., Riazuddin, S. A., & Hassan, S. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.08.004 · Cited by 35
Delivery of gene silencing agents for breast cancer therapy
Shen, H., Mittal, V., Mauro Ferrari, B., & Chang, J. C. (2013) · Breast Cancer Research · doi:10.1186/bcr3413 · Cited by 32
The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery
Zhang, Y., Arrington, L., Boardman, D., Davis, J., Xu, Y., DiFelice, K., Stirdivant, S. M., Wang, W., Budzik, B., Bawiec, J., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.006 · Cited by 31
Genetic associations with lipoprotein subfractions provide information on their biological nature
Petersen, A.-K., Stark, K. J., Musameh, M. D., Nelson, C. P., Römisch‐Margl, W., Kremer, W., Raffler, J., Krug, S., Skurk, T., Rist, M. J., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr580 · Cited by 33
Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics
Marlowe, J. L., Akopian, V., Karmali, P. P., Kornbrust, D. J., Lockridge, J. A., & Semple, S. C. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0671 · Cited by 32
“Thenonhuman primate has been the default choice of nonrodent species for the assessment of oligonucleotide therapeutics, including for formulated oligonucleotides [28,31–33].”
The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs
Weidle, U. H., Epp, A., Birzele, F., & Brinkmann, U. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20108 · Cited by 32
Strategies and materials of "SMART" non-viral vectors: Overcoming the barriers for brain gene therapy
Li, Y., Liu, L., Ji, W., Peng, H., Zhao, R., & Zhang, X. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101006 · Cited by 34
Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles
Tanaka, H., Miyama, R., Sakurai, Y., Tamagawa, S., Nakai, Y., Tange, K., Yoshioka, H., & Akita, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122097 · Cited by 34
Duplex End Breathing Determines Serum Stability and Intracellular Potency of siRNA–Au NPs
Patel, P. C., Hao, L., Yeung, W. S. A., & Mirkin, C. A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200084y · Cited by 32
Silica nanogelling of environment-responsive PEGylated polyplexes for enhanced stability and intracellular delivery of siRNA
Gouda, N. A., Miyata, K., Christie, R. J., Suma, T., Kishimura, A., Fukushima, S., Nomoto, T., Liu, X., Nishiyama, N., & Kataoka, K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.077 · Cited by 33
Broad-Spectrum Antiviral Activity of RNA Interference against Four Genotypes of Japanese Encephalitis Virus Based on Single MicroRNA Polycistrons
Wú, Z., Xue, Y., Wang, B., Du, J., & Jin, Q. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026304 · Cited by 32
“Many local and systemic delivery methods for siRNAs or siRNA-encoding plasmids, such as lipid-based delivery, viral vector-based delivery, cell-penetrating peptide-based delivery, and poly (lactic-co-glycolic acid) (PLGA) nanoparticle-based delivery have been reported in the past few years [26,38,39,40,41], but there…”
Background
Application of nanoparticle technology in the treatment of Systemic lupus erythematous
Rostamzadeh, D., Razavi, S. R., Esmaeili, S., Dolati, S., Ahmahi, M., Sadreddini, S., Jadidi‐Niaragh, F., & Yousefi, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.08.020 · Cited by 34
“Allogeneic CD4+ T cells in cultured with these DCs, exhibited low proliferative capacity liposomes accumulate in the liver and silence target genes [124,125].”
Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases
Carneiro, S. P., Greco, A., Chiesa, E., Genta, I., & Merkel, O. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2185220 · Cited by 33
Gene therapy then and now: A look back at changes in the field over the past 25 years
Wang, D., Stevens, G., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.040 · Cited by 34
“These issues were effectively overcome, at least for targeting hepatocytes of the liver by chemical RNA modi ﬁ cations, 59 conjugation with the GalNAc targeting ligand, 60 and augmenting LNP delivery technologies, 61 ultimately leading to six FDA-approved siRNA therapies since 2018.”
Novel HIV-1 therapeutics through targeting altered host cell pathways
Coley, W., Kehn‐Hall, K., Duyne, R. V., & Kashanchi, F. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903257781 · Cited by 31
“used siRNAs delivered by intravenous injection to knock down the endogenous ApoB protein in cynomolgus monkey liver cells [134].”
Determination of key structure–activity relationships in siRNA delivery with a mixed micelle system
Omedes‐Pujol, M., Coleman, D. J. L., Allen, C. D., Heidenreich, O. T., & Fulton, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.013 · Cited by 31
“Numerous systems have been developed with the aim of overcoming the problem of effective siRNA delivery including liposomes [9,10], cell penetrating peptides [11,12] and polymer nanoparticle-based systems [13].”
MicroRNAs in Liver Health and Disease
Hsu, S., & Ghoshal, K. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-012-0005-4 · Cited by 32
“[77] have used SNALP-mediated delivery of siRNA to target hepatic APOB in non-human primates.”
Method
Silencing Mitogen-Activated Protein Kinase-Activated Protein Kinase-2 Arrests Inflammatory Bone Loss
Li, Q., Yu, H. H., Zinna, R. A., Martin, K. L., Herbert, B. A., Liu, A., Rossa, C., & Kirkwood, K. L. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.172395 · Cited by 30
“…lasted 5 days (Christoph et al., 2006). siRNA against apolipoprotein B was active in mice for only a few days, and after 9 days apolipoprotein B approached 70% of its initial level, whereas apolipoprotein B knockdown in nonhuman primates was still effective after 11 days (Zimmermann et al., 2006).”
Background
Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics
Sato, Y., Sakurai, Y., Kajimoto, K., Nakamura, T., Yamada, Y., Akita, H., & Harashima, H. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600179 · Cited by 32
The hydrophobic tail of a pH-sensitive cationic lipid influences siRNA transfection activity and toxicity in human NK cell lines
Nakamura, T., Nakade, T., Yamada, K., Sato, Y., & Harashima, H. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121140 · Cited by 31
siRNA therapeutics: insights, challenges, remedies and future prospects
Khan, S., Rehman, U., Parveen, N., Kumar, S., Baboota, S., & Ali, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2251890 · Cited by 34
“Stable Nucleic Acid Lipid Particles (SNALPs) : SNALPs are highly PEGylated cationic liposomes with a diameter of 70– 150 nm that are advanced for siRNA delivery and were developed by Tekmira Pharmaceuticals Corporation [57–62].”
siRNA-Like Double-Stranded RNAs Are Specifically Protected Against Degradation in Human Cell Extract
Hoerter, J. A. H., Krishnan, V., Lionberger, T. A., & Walter, N. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020359 · Cited by 33
“silencing through the RNAi pathway [7–18].”
MicroRNA and Brain Tumors: A Cause and a Cure?
Mathupala, S. P., Mittal, S., Guthikonda, M., & Sloan, A. E. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0560 · Cited by 31
c-Jun Is Critical for the Progression of Osteosarcoma: Proof in an Orthotopic Spontaneously Metastasizing Model
Dass, C. R., Khachigian, L. M., & Choong, P. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0036 · Cited by 30
Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Abaza, T., Mohamed, E., & Zaky, M. Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02939-3 · Cited by 35
“Subse-quently, the development of the DLinDMA lipid enabled the initial successful demonstration of RNA interference in primates through a systemically administered LNPs [22].”
Effects of Moisture Content on the Storage Stability of Dried Lipoplex Formulations
Yu, J., & Anchordoquy, T. J. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21846 · Cited by 30
siRNAs: Potential therapeutic agents against Hepatitis C Virus
Ashfaq, U. A., Yousaf, M. Z., Aslam, M., Ejaz, R., Jahan, S., & Ullah, O. (2011) · Virology Journal · doi:10.1186/1743-422x-8-276 · Cited by 30
“Results reported from a number of model organisms are quite promising [22-25] and even in recent clinical trials, but it is quite early to foretell the outcome of these challenging efforts.”
Result
Bioengineered Extracellular Membranous Nanovesicles for Efficient Small‐Interfering RNA Delivery: Versatile Platforms for Stem Cell Engineering and In Vivo Delivery
Jin, Y., Lee, J. S., Min, S., Park, H., Kang, T. J., & Cho, S. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201601430 · Cited by 30
Nucleic acid combinations: A new frontier for cancer treatment
Remant Bahadur, K. C., Thapa, B., Valencia‐Serna, J., Aliabadi, H. M., & Uludağ, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.029 · Cited by 30
The function of long non-coding RNAs in vascular biology and disease
Kok, F. O., & Baker, A. H. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2018.06.004 · Cited by 30
Tiling genomes of pathogenic viruses identifies potent antiviral shRNAs and reveals a role for secondary structure in shRNA efficacy
Tan, X., Lu, Z. J., Gao, G., Xu, Q., Hu, L., Fellmann, C., Li, M. Z., Qu, H., Lowe, S. W., Hannon, G. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119873109 · Cited by 29
Delivery of Therapeutic RNAi by Nanovehicles
Baigude, H., & Rana, T. M. (2009) · ChemBioChem · doi:10.1002/cbic.200900252 · Cited by 30
Exon Skipping of Hepatic APOB Pre-mRNA With Splice-switching Oligonucleotides Reduces LDL Cholesterol In Vivo
Disterer, P., Al‐Shawi, R., Ellmerich, S., Waddington, S. N., Owen, J. S., Simons, J. P., & Khoo, B. C. E. (2013) · Molecular Therapy · doi:10.1038/mt.2012.264 · Cited by 30
“34 None of these approaches is selective for APOB100, and each could potentially cause down-regulation of all APOB expression, including the APOB48 isoform necessary for fat and fat-soluble vitamin absorption.”
Age-Related Macular Degeneration and the Other Double Helix The Cogan Lecture
Ambati, J. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7328 · Cited by 30
One-step encapsulation of siRNA between lipid-layers of multi-layer polycation liposomes by lipoplex freeze-thawing
Koide, H., Okamoto, A., Tsuchida, H., Ando, H., Ariizumi, S., Kiyokawa, C., Hashimoto, M., Asai, T., Dewa, T., & Oku, N. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.032 · Cited by 30
“Since siRNA is degraded in the bloodstream by RNases and has little transfection efficiency owing to its low permeation through the plasma membrane [4, 5], cationic liposomes, polycations and lipidic nanoparticles have been used as a siRNA delivery vector to overcome these problems [5-8].”
Black phosphorus nanoplatform coated with platelet membrane improves inhibition of atherosclerosis progression through macrophage targeting and efferocytosis
Zhang, J., Wang, Z., Liao, Y., Tong, J., Gao, R., Zeng, Z., Bai, Y., Wei, Y., & Guo, X. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.11.041 · Cited by 29
Development of RNA Interference–Based Therapeutics and Application of Multi-Target Small Interfering RNAs
Li, T., Wu, M., Zhu, Y. Y., Chen, J., & Chen, L. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0480 · Cited by 29
“In the past 5 years, the development pipeline has shifted from local to systemic delivery as more advanced delivery vehicles become available for systemic applications, including stable nucleic acid lipid particles (SNALP) (Zimmermann et al., 2006) and RNA/oligonucleotide nano-particle delivery (RONDEL) (Heidel et al.…”
New light labile linker for solid phase synthesis of 2′-O-acetalester oligonucleotides and applications to siRNA prodrug development
Johnsson, R., Lackey, J. G., Bogojeski, J. J., & Damha, M. J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.073 · Cited by 29
Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery
Chang, T.-Y., Shi, P., Steinmeyer, J. D., Chatnuntawech, I., Tillberg, P. W., Love, K. T., Eimon, P. M., Anderson, D. G., & Yanik, M. F. (2014) · Integrative Biology · doi:10.1039/c4ib00150h · Cited by 29
Harnessing RNAi nanomedicine for precision therapy
Peer, D. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-5 · Cited by 29
“Several RNAi-based clinical trials utilize naked RNAi molecules with local delivery (Table 1), yet, a great promise for the entire RNAi field is based on systemic administration and vast progress has been made using non-human primate models [49,91-95].”
Immune responses of therapeutic lipid nanoparticles
Chen, W. C., May, J. P., & Li, S. (2012) · Nanotechnology Reviews · doi:10.1515/ntrev-2012-0040 · Cited by 29
Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier
Matsui, H., Sato, Y., Hatakeyama, H., Akita, H., & Harashima, H. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.044 · Cited by 29
Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy
Maczuga, P., Lubelski, J., van Logtenstein, R., Borel, F., Blits, B., Fakkert, E., Costessi, A., Butler, D., van Deventer, S. J. H., Petry, H., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.160 · Cited by 29
“ApoB is a constituent of all classes of lipoproteins that are considered atherogenic and elevated ApoB levels have been demonstrated to correlate with increased risk of cardiovascular disease (CVD) [30].”
Background
Apolipoprotein B Knockdown by AAV-delivered shRNA Lowers Plasma Cholesterol in Mice
Koornneef, A., Maczuga, P., van Logtenstein, R., Borel, F., Blits, B., Ritsema, T., van Deventer, S. J. H., Petry, H., & Konstantinova, P. S. (2011) · Molecular Therapy · doi:10.1038/mt.2011.6 · Cited by 32
“Inclusion of siApoB in liposomal formulations is another highly effective approach for ApoB silencing in the liver [16].”
Background
Acid-Degradable Cationic Poly(ketal amidoamine) for Enhanced RNA Interference In Vitro and In Vivo
Lim, H., Noh, J., Kim, Y., Kim, H., Kim, J.-H., Khang, G., & Lee, D. (2012) · Biomacromolecules · doi:10.1021/bm301669e · Cited by 29
Inhibition of wild-type p66ShcA in mesangial cells prevents glycooxidant-dependent FOXO3a regulation and promotes the survival phenotype
Chintapalli, J., Yang, S., Opawumi, D., Goyal, S., Shamsuddin, N., Malhotra, A., Reiss, K., & Meggs, L. G. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00215.2006 · Cited by 28
Bifunctional pH-sensitive Zn(ii)–curcumin nanoparticles/siRNA effectively inhibit growth of human bladder cancer cells in vitro and in vivo
Xing, Z.-H., Wei, J., Cheang, T., Wang, Z., Zhou, X. Y., Wang, S., Chen, W., Wang, S., Luo, J., & Xu, A. (2014) · Journal of Materials Chemistry B · doi:10.1039/c3tb21625j · Cited by 29
Targeted Delivery to Neuroblastoma of Novel siRNA-anti-GD2-liposomes Prepared by Dual Asymmetric Centrifugation and Sterol-Based Post-Insertion Method
Adrian, J. E., Wolf, A., Steinbach, A., Rössler, J. K., & Süss, R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0457-y · Cited by 29
SiRNA Delivery Systems Based on Neutral Cross-Linked Dendrimers
Liu, J., Zhou, J., & Luo, Y. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200433s · Cited by 29
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 33
“In 2006, the siRNA delivery commenced with apolipoprotein B speciﬁc siRNA encapsulated using stable nucleic acid lipid particles (SNALP) to silence diseases in non-human primates through intravenous administration 87 .”
Method
Albumin pre-coating enhances intracellular siRNA delivery of multifunctional amphiphile/siRNA nanoparticles
Lu, Z., Kummitha, C. M., & Malamas (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s34288 · Cited by 28
Retracted
Trends in polymeric delivery of nucleic acids to tumors
Yousefi, A., Storm, G., Schiffelers, R. M., & Mastrobattista, E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.040 · Cited by 30
Therapeutic angiogenesis by local sustained release of microRNA-126 using poly lactic-co-glycolic acid nanoparticles in murine hindlimb ischemia
Tsumaru, S., Masumoto, H., Minakata, K., Izuhara, M., Yamazaki, K., Ikeda, T., Ono, K., Sakata, R., & Minatoya, K. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.08.097 · Cited by 28
Metabolism of bioconjugate therapeutics: why, when, and how?
Liu, H., Bolleddula, J., Nichols, A. J., Tang, L., Zhao, Z., & Prakash, C. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1716784 · Cited by 29
“Once inside a cell, the active strand of the siRNA incorporated into the RNA-induced silencing complex appears incredibly stable, since silencing in some tissues persists for weeks (Song et al. 2003; Palliser et al. 2006; Zimmermann et al. 2006).”
Background
Nanotechnological approach to delivering nutraceuticals as promising drug candidates for the treatment of atherosclerosis
Pillai, S. C., Borah, A., Jacob, E. M., & Kumar, D. S. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1892241 · Cited by 29
“Since conventional therapies are limited in their efficacy to target Apo B, the delivery of liposome encapsulating anti-Apo B siRNA can silence Apo B to reduce the circulatory LDL (Zimmermann et al., 2006).”
Background
Liposomal Formulations for Nucleic Acid Delivery
MacLachlan, I. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-16 · Cited by 57
Systemic siRNA delivery to leukocyte-implicated diseases
Peer, D., & Shimaoka, M. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7936 · Cited by 28
Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis
Scamuffa, N., Sfaxi, F., Ma, J., Lalou, C., Seidah, N. G., Calvo, F. M., & Khatib, A. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt345 · Cited by 28
Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C
Yokota, T., Iijima, S., Kubodera, T., Ishii, K., Katakai, Y., Ageyama, N., Chen, Y., Lee, Y.-J., Unno, T., Nishina, K., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.182 · Cited by 27
Nano-carriers for drug routeing – towards a new era
Reddy, L. H., & Bazile, D. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1561891 · Cited by 28
Therapeutic Rna Manipulation in Liver Disease
Kerr, T. A., & Davidson, N. O. (2009) · Hepatology · doi:10.1002/hep.23344 · Cited by 28
Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology
Gomes-da-Silva, L. C., Simões, S., & Moreira, J. N. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1502-2 · Cited by 27
Development of Lipid Nanoparticles for the Delivery of Macromolecules Based on the Molecular Design of pH-Sensitive Cationic Lipids
Sato, Y. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00705 · Cited by 29
Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia
Thomas, T. A., & Ginsberg, H. N. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0078-7 · Cited by 27
Solid-Phase Synthesis and On-Column Deprotection of RNA from 2‘- (and 3‘-) O -Levulinated (Lv) Ribonucleoside Monomers
Lackey, J. G., Sabatino, D. A., & Damha, M. J. (2007) · Organic Letters · doi:10.1021/ol0629521 · Cited by 27
Phosphorothioate-Stimulated Cellular Uptake of siRNA: A Cell Culture Model for Mechanistic Studies
Detzer, A., Overhoff, M. G., Mescalchin, A., Rompf, M., & Sczakiel, G. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786898770 · Cited by 27
“In general, synthetic siRNA can be delivered using different approaches including cell penetrating peptides [1,25- 28], proteamine-antibody fusion proteins [29-31], atelocollagen [32-34], cholesterol conjugation [ 35-37 ] and stable nucleic acid-lipid particles [38-40].”
Background
Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins
Harchaoui, K. E., Akdim, F., Stroes, E. S. G., Trip, M. D., & Kastelein, J. J. P. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808040-00003 · Cited by 27
Quantitative measurement of delivery and gene silencing activities of siRNA polyplexes containing pyridylthiourea-grafted polyethylenimines
Pinel, S., Aman, E., Erblang, F., Dietrich, J., Frisch, B., Sirman, J., Kichler, A., Sibler, A., Dontenwill, M., Schaffner, F., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.001 · Cited by 27
Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines
Hazan‐Halevy, I., Landesman‐Milo, D., Rosenblum, D., Mizrahy, S., Ng, B. D., & Peer, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.052 · Cited by 27
Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy
Dass, C. R., Galloway, S. J., Clark, J. C. M., Khachigian, L. M., & Choong, P. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.8.6301 · Cited by 27
The Medicinal Chemistry of Oligonucleotides
Swayze, E. E., & Bhat, B. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-13 · Cited by 26
Advances in Predictive, Preventive and Personalised Medicine
Karabulut, S. (2012) · Cited by 26
siRNA-Chitosan Complexes in Poly(lactic-co-glycolic acid) Nanoparticles for the Silencing of Aquaporin-1 in Cancer Cells
Stigliano, C., Aryal, S., Tullio, M. D. D., Nicchia, G. P., Pascazio, G., Svelto, M., & Decuzzi, P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400224u · Cited by 26
Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01
Ashizawa, A. T., & Cortes, J. E. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.996545 · Cited by 26
“SNALPs are composed of an ionizable cationic lipid, phosphatidylcholine and cholesterol [28].”
Background
Efficient Intracellular Delivery of siRNA with A Safe Multitargeted Lipid-Based Nanoplatform
Gomes-da-Silva, L. C., Fernández, Y., Abasolo, I., Schwartz, S., Ramalho, J. S., de Lima, M. C. P., Simões, S., & Moreira, J. N. (2013) · Nanomedicine · doi:10.2217/nnm.12.174 · Cited by 26
Next-generation Nanotheranostics Targeting Cancer Stem Cells
Reda, A. M., Hosseiny, S., & El-sherbiny, I. M. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0443 · Cited by 26
Quantification of siRNA using competitive qPCR
Liu, W., Stevenson, M., Seymour, L. W., & Fisher, K. D. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn903 · Cited by 26
“RNAi is facilitating our understanding of functional genomics and offers potential for therapy by targeting disease-associated genes (4,5).”
Background
RNA interference based gene therapy for neurological disease
Jagannath, A., & Wood, M. J. A. (2007) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/elm005 · Cited by 25
Microenvironment‐Programmed siRNA‐Based Hydrogel for Spatiotemporal Gene Silencing in Wound Healing
Xu, Z., Yang, W., Zhang, R., Zhang, G., Liang, X., Zhao, N., Chen, X., Li, Y., & Xu, F. (2025) · Advanced Materials · doi:10.1002/adma.202509558 · Cited by 28
Impact of PEGylation on biodistribution and tumor accumulation of Lipid-Mu peptide-DNA
Bai, J. Y., Zhou, Z., Tang, H., Song, S., Peng, J., & Xu, Y. (2012) · Journal of Liposome Research · doi:10.3109/08982104.2012.708934 · Cited by 25
Gene Therapies for Polyglutamine Diseases
Matos, C. A., Carmona, V., Vijayakumar, U. G., Lopes, S., Albuquerque, P., Conceição, M., Nobre, R. J., Nóbrega, C., & de Almeida, L. P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-71779-1_20 · Cited by 25
Octreotide-Targeted Lcn2 siRNA PEGylated Liposomes as a Treatment for Metastatic Breast Cancer
Gote, V., & Pal, D. (2021) · Bioengineering · doi:10.3390/bioengineering8040044 · Cited by 25
“They can (i) protects siRNA from degradation, thus increase circulation t1/2 (ii) entrap hydrophilic and hydrophobic cargo, (iii) low immune response, (iv) evasion of reticuloendothelial system, (v) cationic liposomes can protect siRNA from attack by endonucleases (vi) can achieve enhanced permeability and retention (…”
Background
Gene interference strategies as a new tool for the treatment of prostate cancer
Boccellino, M., Alaia, C., Misso, G., Cossu, A. M., Facchini, G., Piscitelli, R., Quagliuolo, L., & Caraglia, M. (2015) · Endocrine · doi:10.1007/s12020-015-0629-3 · Cited by 25
“SNALPs have been successfully proposed to deliver small interfering RNAs in non-human primates [96] and clinical trials are currently ongoing.”
Background
Effective Nanoparticle‐based Gene Delivery by a Protease Triggered Charge Switch
Gjetting, T., Jølck, R. I., & Andresen, T. L. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300503 · Cited by 25
RNA interference as an anticancer therapy: a patent perspective
Dykxhoorn, D. M. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902838008 · Cited by 25
“A similar strategy was used to deliver anti-ApoB siRNAs to the liver of non-human primates leading to a reduction of ApoB protein expression and a concomitant decrease in the levels of serum cholesterol and low-density lipoproteins [127].”
Method
RNA‐Interferenz: von den Grundlagen zur therapeutischen Anwendung
Kurreck, J. (2009) · Angewandte Chemie · doi:10.1002/ange.200802092 · Cited by 26
Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: A mini-review
Peer, D. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.06.029 · Cited by 25
Exploring in vitro roles of siRNA in cardiovascular disease
Tang, Y., Ge, Y.-Z., & Yin, J. Q. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00491.x · Cited by 25
Nucleic acid therapies for cystic fibrosis
Sasaki, S., & Guo, S. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0696 · Cited by 24
“Other ligand conjugation approaches to additional cell types and tissues are under investigation. siRNAs siRNAs are therapeutically validated double-stranded RNA oligonucleotides that mediate degradation of the target mRNA [15,16] (Fig.”
Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs
Nikitenko, N. A., & Prassolov, V. (2013) · Acta Naturae · doi:10.32607/20758251-2013-5-3-35-53 · Cited by 24
Targeted Delivery of RNAi Therapeutics for Cancer Therapy
Li, J., & Huang, L. (2010) · Nanomedicine · doi:10.2217/nnm.10.124 · Cited by 24
Targeting RPTPσ with lentiviral shRNA promotes neurites outgrowth of cortical neurons and improves functional recovery in a rat spinal cord contusion model
Zhou, H., Li, X., Li, F., Liu, C., Liang, Z., Liu, S., Zhang, B., Wang, T., Chu, T., Lu, L., et al. (2014) · Brain Research · doi:10.1016/j.brainres.2014.08.048 · Cited by 24
Synthesis of Lipid–Oligonucleotide Conjugates for RNA Interference Studies
Grijalvo, S., Ocampo, S. M., Perales, J. C., & Eritja, R. (2011) · Chemistry & Biodiversity · doi:10.1002/cbdv.201000274 · Cited by 24
Novel directions in inflammation as a therapeutic target in atherosclerosis
Verweij, S. L., van der Valk, F. M., & Stroes, E. S. G. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000233 · Cited by 24
“In the preclinical realm, liposomal nanoparticles loaded with siRNA targeted to CCR2 [43] and ApoB [60] and liposomal nanoparticle loaded with prednisolone phosphate (LN-PLP) [61] have shown favorable effects on experimental atherosclerosis.”
Background
Local application of Usag-1 siRNA can promote tooth regeneration in Runx2-deficient mice
Mishima, S., Takahashi, K., Kiso, H., Murashima-Suginami, A., Tokita, Y., Jo, J.-I., Uozumi, R., Nambu, Y., Huang, B., Harada, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93256-y · Cited by 34
Technologies for Investigating the Physiological Barriers to Efficient Lipid Nanoparticle–siRNA Delivery
Shi, B., & Abrams, M. T. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413484152 · Cited by 24
“The results from a variety of preclinical studies indicate that LNP is broadly distributed in all tissues, with preferential delivery and accumulation in the liver and spleen (Zimmermann et al. 2006; Davis et al. 2010; Abrams et al. 2010; Tao et al. 2010; Tao et al. 2011).”
Background
Combined Analysis of Polycation/ODN Polyplexes by Analytical Ultracentrifugation and Dynamic Light Scattering Reveals their Size, Refractive Index Increment, Stoichiometry, Porosity, and Molecular Weight
Niebel, Y., Buschmann, M. D., Lavertu, M., & Crescenzo, G. D. (2014) · Biomacromolecules · doi:10.1021/bm4018148 · Cited by 24
A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5′ RACE and a molecular beacon probe
Lasham, A., Herbert, M., Coppieters, N., Patel, R., Feng, S. X., Eszes, M., Cao, H., & Reid, G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1076 · Cited by 24
“5 mg/kg both in mice and in non-human primates (16).”

Authors: Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H.-P., & MacLachlan, I.
Affiliations: Alnylam Pharmaceuticals (United States) (US)
Electronic Arts (Canada) (CA)
Corresponding author: Zimmermann, Tracy S.
MacLachlan, Ian
ORCID: Lee, Amy C. H.
Fedoruk, Matthew N.
Harborth, Jens
Heyes, James A.
Lam, Kieu
McClintock, Kevin
Palmer, Lorne R.
Manoharan, Muthiah
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2006-03-26
Volume: 441
Issue: 7089
Pages: 111-114
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature04688
OpenAlex: W2095151181
Cited by: 1,357
References: 20
Citations by year: 2026: 21 · 2025: 22 · 2024: 30 · 2023: 42 · 2022: 40 · 2021: 35 · 2020: 35 · 2019: 46 · 2018: 30 · 2017: 47 · 2016: 54 · 2015: 70 · 2014: 97 · 2013: 113 · 2012: 111
FWCI: 46.06
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Alnylam Pharmaceuticals
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: RNA interference, gene silencing, siRNA, apolipoprotein B, siRNA therapeutics, systemic siRNA delivery, Macaca fascicularis, non-human primates, hypercholesterolemia, LDL cholesterol, B-cell lymphoma, CARD11
MeSH terms: Animals, Apolipoproteins B, Phenotype, Primates, RNA, Messenger, RNA Interference, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RNAi-mediated gene silencing in non-human primates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks